The Company today announced a collaboration with Memorial Sloan Kettering Cancer Center to screen the T cell responses of melanoma and non-small cell lung cancer patients treated with checkpoint inhibitors against the complete repertoire of patient-specific putative cancer neoantigens. This retrospective analysis of 10 checkpoint inhibitor (CPI) treated patients’ T cell responses to 23 known tumor-associated antigens, analyzed the immune responses of both responders and non-responders to CPI therapy. Department of Defense and the Bill and Melinda Gates Foundation. Nach Testung von Einmalgaben wird in einem weiteren Teil der Studie die Mehrfachgabe mit steigenden Dosierungen an 36 Teilnehmern untersucht. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Symptoms may affect people for several months and are mainly caused by an exacerbated immune reaction to infected cells. Genocea announced in February 2015 the appointment of Michael Higgins to its board of directors.
It is devoted to research and clinical development of innovative and resistance-breaking drugs for the treatment of HCMV, Herpes, Hepatitis B, HIV and Hepatitis C as well as resistant Gram positive and Gram negative bacterial infections in hospitals. We first saw Dr. Median clearance slope from episode peak to termination was higher in 25 mg, 75 mg and 400 mg weekly than placebo and 5 mg daily (). Rosanna Kapeller, chief scientific officer of Nimbus Discovery, wrote an interesting blog about how Intercept is establishing a road map with the FDA which other companies will be able to follow. These forward-looking statements represent the Company’s judgment as of the date of this release. For more information on Astellas Pharma Inc., please visit www.astellas.com/en. Net Loss: Net loss was $12.8 million for the third quarter ended September 30, 2016, compared to a net loss of $9.8 million for the same period in 2015.
AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs against infectious diseases. The primary endpoint of the study is annualized lesion recurrence rate and was selected following consultation with clinical experts and the FDA. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Each of the 80 or so proteins in the herpes simplex 2 genome is a possibility, as are the thousand or so proteins in chlamydia and the 5,000 or so in malaria. About Vical Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. The Human Cytomegalovirus (HCMV) is widely spread in the human population and can cause severe, life-threatening infections in cases of immune incompetency or immune deficiency, such as, for example, cases in transplant recipients, newborn babies and HIV/AIDS patients. Their consensus pricet target is $15.
coli can be engineered to direct antigens to the cytosol of human antigen presenting cells for processing. Pritelivir is an innovative, highly active and specific inhibitor of herpes simplex virus (HSV). Invited participants may ask questions during the conference call. It has pre-clinical development programs, which include GEN-001, which is indicated for the treatment of chlamydia prophylaxis, and GEN-002, which indicated for the treatment of genital herpes prophylaxis both of which are in pre-clinical stage of development. Moreover, resistance develops occasionally in immunocompromised subjects, such as transplant recipients or HIV-infected subjects. On the same day Genocea released their announcement, BD announced their filing for 501k clearance for an automated molecular test to diagnose and differentiate between HSV-1 and HSV-2. Today, Genocea highlighted the significant body of clinical data it has generated over the course of three clinical trials for what may be the first new therapy for genital herpes in more than 20 years.
Up to 40 percent of untreated women develop pelvic inflammatory disease, which can lead to infertility, ectopic pregnancies, and chronic pelvic pain. The Phase 2 trial has been designed based on Phase 1/2 trial results presented at the 2016 American Society for Microbiology (ASM/ICAAC) Microbe Meeting in June that revealed a statistically significant reduction (-57%, p = 0.009) in lesion rate compared to baseline in the bivalent vaccine arm at 9 months, along with favorable trends in recurrence rate, time to first recurrence, and proportion of subjects who were recurrence-free. has recruited 46 volunteers who are being treated for 21 consecutive days with topical pritelivir. Pritelivir (oral) has already shown superiority against the standard of care, valaciclovir, in a phase 2 trial in patients with genital HSV-2 infections. “Anza” Mammen, Jr., M.D., Vical’s Vice President, Clinical Vaccines, will be accessible on Vical’s website. In the double-blind, randomized crossover study 91 participants with recurrent genital herpes but not with an active outbreak were randomized to receive daily oral doses of 100 mg pritelivir over 28 days followed by a 28-day wash-out period before taking 500 mg valacyclovir for 28 days (n=46) or to start the treatment cycle with valacyclovir first (n=45).